| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bacterial ribosomes (50S subunit). Mycaminosyltylonolide inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. It is a macrolide antibiotic that prevents the translocation step of protein elongation.
|
|---|---|
| ln Vitro |
In E. coli, mycaminosyltylonolid (3 µM) suppresses the translation of firefly luciferase mRNA. Coli S30 [1]. MIC values of 1 and 1 against S indicate the antibacterial activity of mycaminosyltylonolid (0-128 µg/mL). aureus FDA209Pa, S. aureus Smitha, S. aureus KUB857c, S. skindamus KUB795g, E. For K. faecalis ATCC29212h. pneumoniae NCTC9632h and so forth. 64 µg/mL, 1, 2, 2, 1, [2].
Mycaminosyltylonolide (3 µM) inhibits firefly luciferase mRNA translation in E. coli. It exhibits antibacterial activity against various Gram-positive bacteria. Detailed MIC values against specific pathogens are available from specialized databases. |
| ln Vivo |
In vivo activity data for Mycaminosyltylonolide is not extensively detailed in the literature. As a macrolide antibiotic, it is expected to show efficacy in animal models of bacterial infections. It is an intermediate in tylosin biosynthesis, suggesting it may have similar pharmacological properties to tylosin.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing is performed using standard broth microdilution methods. The compound is serially diluted in 96-well plates, and bacterial cultures are added. The minimum inhibitory concentration (MIC) is determined.
|
| Cell Assay |
In vitro assays for protein synthesis inhibition are performed using cell-free translation systems or bacterial cultures. Luciferase reporter assays are used to measure translation inhibition. Bacteria are treated with the compound, and luciferase activity is measured.
|
| Animal Protocol |
In vivo efficacy studies are performed in mouse models of infection (e.g., peritonitis or thigh infection models). Mycaminosyltylonolide is administered subcutaneously or intramuscularly. Bacterial load in tissues is quantified. Survival rates are monitored.
|
| ADME/Pharmacokinetics |
Mycaminosyltylonolide has a molecular weight of 597.74 and a molecular formula of C31H51NO10. It is a 16-membered macrolide. It is soluble in DMSO. Detailed pharmacokinetic parameters such as oral bioavailability and half-life are available from specialized databases. It is stored at -20°C.
|
| Toxicity/Toxicokinetics |
Detailed toxicological profiles of Mycaminosyltylonolide are not extensively reported. As a macrolide antibiotic, it is expected to have a manageable safety profile. Macrolides are generally well-tolerated, but may cause gastrointestinal disturbances and, rarely, hepatotoxicity.
|
| References |
|
| Additional Infomation |
5-O-macaminol tylosin is a macrolide antibiotic consisting of a β-D-macaminol residue linked at the 5-position of tylosin. It is a macrolide antibiotic, a monosaccharide derivative, an enone, and an aldehyde. Functionally, it is related to tylosin. It is the conjugate base of 5-O-macaminol tylosin (1+).
Mycaminosyltylonolide is a research-grade macrolide antibiotic. It is used as an intermediate in the synthesis of other macrolide antibiotics and as a tool to study bacterial protein synthesis. It is not approved for clinical use. Its molecular formula is C31H51NO10 and its molecular weight is 597.74. |
| Molecular Formula |
C31H51NO10
|
|---|---|
| Molecular Weight |
597.74
|
| Exact Mass |
597.351
|
| CAS # |
61257-02-1
|
| PubChem CID |
6437420
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2g/cm3
|
| Boiling Point |
799.9ºC at 760 mmHg
|
| Flash Point |
437.6ºC
|
| Index of Refraction |
1.545
|
| LogP |
1.402
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
42
|
| Complexity |
952
|
| Defined Atom Stereocenter Count |
12
|
| SMILES |
CC[C@@H]1[C@H](/C=C(/C=C/C(=O)[C@@H](C[C@@H]([C@@H]([C@H]([C@@H](CC(=O)O1)O)C)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)C)O)N(C)C)O)CC=O)C)\C)CO
|
| InChi Key |
WGUJDBLMJBJUQU-VKRLOHBMSA-N
|
| InChi Code |
InChI=1S/C31H51NO10/c1-8-25-22(16-34)13-17(2)9-10-23(35)18(3)14-21(11-12-33)30(19(4)24(36)15-26(37)41-25)42-31-29(39)27(32(6)7)28(38)20(5)40-31/h9-10,12-13,18-22,24-25,27-31,34,36,38-39H,8,11,14-16H2,1-7H3/b10-9+,17-13+/t18-,19+,20-,21+,22-,24-,25-,27+,28-,29-,30-,31+/m1/s1
|
| Chemical Name |
2-[(4R,5S,6S,7R,9R,11E,13E,15R,16R)-6-[(2R,3R,4S,5S,6R)-4-(dimethylamino)-3,5-dihydroxy-6-methyloxan-2-yl]oxy-16-ethyl-4-hydroxy-15-(hydroxymethyl)-5,9,13-trimethyl-2,10-dioxo-1-oxacyclohexadeca-11,13-dien-7-yl]acetaldehyde
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 100 mg/mL (167.30 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6730 mL | 8.3648 mL | 16.7297 mL | |
| 5 mM | 0.3346 mL | 1.6730 mL | 3.3459 mL | |
| 10 mM | 0.1673 mL | 0.8365 mL | 1.6730 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
